180 Life Sciences Corp. (ATNF) saw an amazing push of 19.78% in the premarket. However, the last trading session closed at $5.41 with an increase of 21.3%.
Patent Portfolio Expanded by ATNF – What’s going on?
ATNF announced on 22nd November 2021 that the company has expanded its patent portfolio. Patients with established rheumatoid arthritis (RA) who have not responded well to traditional therapy are the first focus. Furthermore, anti-TNF biologics have been demonstrated in several trials to be quite efficient in treating joint inflammation in 60-70 percent of patients, and RA has a 1% impact on the worldwide population. Lastly, the company thinks that SCAs might provide a supplementary treatment strategy for treating the unrelenting pain that disables many people by working through distinct pathways than frequently used anti-inflammatory RA drugs.
Keynote Address
On 18th November 2021, ATNF reported that Professor Jagdeep Nanchahal will present the keynote address at the International Dupuytren Symposium on Wednesday, December 1, 2021, at 3 pm. Professor Nanchahal will discuss his research into the molecular processes behind Dupuytren’s disease pathogenesis. Hence, this will lead to the discovery of anti-tumor necrosis factor (“TNF”) as a possible treatment target. He’ll also go through the results of the Phase 2a clinical study to determine the best dose, as well as the results of the recently completed phase 2b efficacy trial for patients with the early-stage illness.
Chief Business Officer of ATNF – Who’s it?
ATNF announced on 3rd November 2021 that Quan A. Vu has been appointed as the Chief Business Officer. With 20 years of “hands-on” biopharma expertise, Mr. Vu is a highly adaptable and successful strategy, corporate/business development, finance, and operations leader. He is the consummate dealmaker with a track record of identifying, assessing, shaping, and closing transactions. Moreover, he is a convincing negotiator who orchestrates domestic & global win-win solutions that incorporate a variety of perspectives, expectations, and goals.
Now what?
Quan is a fantastic addition to the management team, and the company is happy to have him on board. With his extensive knowledge of pipeline development, commercial evaluation, and go-to-market strategies. Moreover, ATNF is certain that he will contribute significantly to the efforts to bring innovative medications to market that address unmet needs. Lastly, he also has a proven track record of success in both in-licensing and out-licensing.
